Velindre Cancer Centre
IMPAKT News: AP-1 may be a new hallmark of resistance to endocrine therapy
AP-1 is critical in a switch in the estrogen receptor transcriptional programme
IMPAKT News: Evaluation of MUC1 in breast cancer is feasible and could provide information on therapy response following neoadjuvant chemotherapy
MUC1 expression may serve as a predictive marker in clinical immunotherapy trials
IMPAKT News: Prospective comparison of risk assessment tools in early breast cancer
Correlation analysis from the phase III West German Study Group Plan B trial